MX2017005199A - Conjugados y reactivos de conjugacion. - Google Patents

Conjugados y reactivos de conjugacion.

Info

Publication number
MX2017005199A
MX2017005199A MX2017005199A MX2017005199A MX2017005199A MX 2017005199 A MX2017005199 A MX 2017005199A MX 2017005199 A MX2017005199 A MX 2017005199A MX 2017005199 A MX2017005199 A MX 2017005199A MX 2017005199 A MX2017005199 A MX 2017005199A
Authority
MX
Mexico
Prior art keywords
protein
peptide
group
polyethylene glycol
conjugate
Prior art date
Application number
MX2017005199A
Other languages
English (en)
Spanish (es)
Inventor
Frigerio Mark
Godwin Antony
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1418989.8A external-priority patent/GB201418989D0/en
Priority claimed from GBGB1418986.4A external-priority patent/GB201418986D0/en
Priority claimed from GB1418984.9A external-priority patent/GB2531715A/en
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of MX2017005199A publication Critical patent/MX2017005199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2017005199A 2014-10-24 2015-10-08 Conjugados y reactivos de conjugacion. MX2017005199A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1418989.8A GB201418989D0 (en) 2014-10-24 2014-10-24 Novel conjugation process and reagents
GBGB1418986.4A GB201418986D0 (en) 2014-10-24 2014-10-24 Novel conjugates and novel conjugating reagents
GB1418984.9A GB2531715A (en) 2014-10-24 2014-10-24 Novel drug conjugates
PCT/GB2015/052953 WO2016063006A1 (en) 2014-10-24 2015-10-08 Conjugates and conjugating reagents

Publications (1)

Publication Number Publication Date
MX2017005199A true MX2017005199A (es) 2017-07-26

Family

ID=54337308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005199A MX2017005199A (es) 2014-10-24 2015-10-08 Conjugados y reactivos de conjugacion.

Country Status (15)

Country Link
US (3) US20170290925A1 (cg-RX-API-DMAC7.html)
EP (1) EP3220956B1 (cg-RX-API-DMAC7.html)
JP (1) JP6612860B2 (cg-RX-API-DMAC7.html)
KR (1) KR102513926B1 (cg-RX-API-DMAC7.html)
CN (1) CN107073131B (cg-RX-API-DMAC7.html)
AU (1) AU2015334717B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017005760A2 (cg-RX-API-DMAC7.html)
CA (1) CA2963043A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960741T3 (cg-RX-API-DMAC7.html)
IL (1) IL250644B (cg-RX-API-DMAC7.html)
MX (1) MX2017005199A (cg-RX-API-DMAC7.html)
RU (1) RU2017108448A (cg-RX-API-DMAC7.html)
SG (1) SG11201701342XA (cg-RX-API-DMAC7.html)
WO (1) WO2016063006A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701337B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
JP2019506155A (ja) 2016-01-12 2019-03-07 クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ 治療分子
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3442595A1 (en) * 2016-04-14 2019-02-20 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) * 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
EP4282434A3 (en) 2016-06-06 2024-03-06 Abzena (UK) Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
WO2018181059A1 (ja) 2017-03-30 2018-10-04 日油株式会社 ヘテロ二官能性単分散ポリエチレングリコール及びそれを用いた複合体
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CN111836846B (zh) 2018-03-13 2023-06-13 日油株式会社 在主链和侧链具有单分散聚乙二醇的异双官能性化合物
EP3789401A1 (en) 2019-09-03 2021-03-10 Gamamabs Pharma Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
EP4145134A1 (en) * 2020-04-29 2023-03-08 Araclón Biotech, S. L. Methods for quantification of amyloid beta peptides in plasma by mass spectrometry
GB2594753B (en) 2020-05-27 2022-05-18 Spirea Ltd Antibody-drug conjugates
EP4404974A1 (en) 2021-09-21 2024-07-31 Spirea Limited Antibody-drug conjugates

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
EP1061954B1 (en) * 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
KR100511749B1 (ko) * 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2007018431A2 (en) * 2005-08-05 2007-02-15 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
US20070141134A1 (en) * 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery
MX2009002855A (es) * 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
US8575397B2 (en) * 2007-02-14 2013-11-05 Biocompatibles Uk Limited Derivatisation of biological molecules
GB0922354D0 (en) * 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
WO2012113847A1 (en) * 2011-02-25 2012-08-30 Lonza Ltd Branched linker for protein drug conjugates
CN104906592B (zh) * 2011-02-25 2017-11-03 广州南沙龙沙有限公司 用于蛋白质药物偶联物的支链联接体
GB201210770D0 (en) * 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
US9650331B2 (en) * 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
IN2014DN10428A (cg-RX-API-DMAC7.html) * 2012-06-19 2015-08-21 Polytherics Ltd
IN2015DN02349A (cg-RX-API-DMAC7.html) * 2012-10-24 2015-08-28 Polytherics Ltd
NO2789793T3 (cg-RX-API-DMAC7.html) * 2012-10-24 2018-01-27
KR102356814B1 (ko) * 2013-10-15 2022-01-28 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커

Also Published As

Publication number Publication date
SG11201701342XA (en) 2017-03-30
CA2963043A1 (en) 2016-04-28
EP3220956A1 (en) 2017-09-27
US20170290925A1 (en) 2017-10-12
CN107073131B (zh) 2021-05-25
IL250644B (en) 2020-10-29
KR102513926B1 (ko) 2023-03-23
ES2960741T3 (es) 2024-03-06
IL250644A0 (en) 2017-06-29
JP6612860B2 (ja) 2019-11-27
AU2015334717B2 (en) 2021-02-25
US20240293549A1 (en) 2024-09-05
EP3220956B1 (en) 2023-08-09
ZA201701337B (en) 2018-05-30
WO2016063006A1 (en) 2016-04-28
AU2015334717A1 (en) 2017-04-13
US20200268885A1 (en) 2020-08-27
KR20170075724A (ko) 2017-07-03
BR112017005760A2 (pt) 2017-12-12
CN107073131A (zh) 2017-08-18
RU2017108448A (ru) 2018-11-27
JP2017537062A (ja) 2017-12-14

Similar Documents

Publication Publication Date Title
MX2017005199A (es) Conjugados y reactivos de conjugacion.
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12015502180A1 (en) Wt1-antigen peptide conjugate vaccine
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MY171100A (en) Anti-ceacam5 antibodies and uses thereof
EP4279071A3 (en) Novel cannabinoid formulations
PH12015500243B1 (en) Glycoconjugation processes and compositions
NZ745508A (en) Novel amanitin conjugates
MX2015005810A (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
MX2020010026A (es) Formulaciones de anticuerpos anti-pdl1.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MY165002A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
PH12019502694A1 (en) Anti-trkb antibodies
MX2018010491A (es) Proceso para la preparacion de un conjugado anticuerpo-rifamicina.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
PH12016502592A1 (en) 3'-substituted-abscisic acid derivatives
IN2013DE03665A (cg-RX-API-DMAC7.html)
NZ733839A (en) Amino acid and peptide conjugates and conjugation process
MA39141A1 (fr) Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation